Si T G, Li L, Guo Z, Xu B
Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China.
Zhonghua Nei Ke Za Zhi. 2023 Apr 1;62(4):363-368. doi: 10.3760/cma.j.cn112138-20221024-00780.
In recent years, the incidence of renal cancer has been increasing continuously. Surgical resection is the "gold standard" for the treatment of small renal cancer. However, local ablation therapy of renal cancer is undoubtedly the best choice for patients with short life expectancy, other complications, and impaired renal function who are not suitable for surgery. In recent years, with the development of ablation techniques and long-term follow-up, local ablation has shown good therapeutic effects. As many domestic hospitals are performing or planning to perform renal tumor cryoablation to improve the clinical cure rate and surgical safety of renal tumor cryoablation, it is necessary to standardize the surgical indications, contraindications, perioperative management, efficacy evaluation, and other common problems. Currently, there is no expert consensus regarding perioperative renal tumor cryoablation in China. To standardize the perioperative management of renal tumor cryoablation and related technical operations in clinical practice, and improve the effectiveness and safety of cryoablation, the expert committee of Tumor Interventional and Minimally Invasive Diagnosis and Treatment Continuing Education Base of the Chinese Anti-Cancer Association convened experts in related fields to discuss and formulate this consensus, which is hereby published, for clinical reference and application.
近年来，肾癌的发病率持续上升。手术切除是小肾癌治疗的“金标准”。然而，对于预期寿命短、有其他并发症以及肾功能受损而不适合手术的肾癌患者，局部消融治疗无疑是最佳选择。近年来，随着消融技术的发展和长期随访，局部消融已显示出良好的治疗效果。由于国内许多医院正在开展或计划开展肾肿瘤冷冻消融术以提高肾肿瘤冷冻消融术的临床治愈率和手术安全性，规范手术适应证、禁忌证、围手术期管理、疗效评估等常见问题很有必要。目前，我国尚无关于肾肿瘤冷冻消融术围手术期的专家共识。为规范肾肿瘤冷冻消融术在临床实践中的围手术期管理及相关技术操作，提高冷冻消融的有效性和安全性，中国抗癌协会肿瘤介入与微创诊断治疗继续教育基地专家委员会召集相关领域专家进行讨论并制定本共识，现予发布，供临床参考应用。
